HCW Biologics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by HCW Biologics Inc. on June 18, 2025, with a signature date of July 1, 2025. The filing addresses the final exercise of pre-funded warrants under a Securities Purchase Agreement entered into on May 13, 2025, with Armistice Capital Master Fund Ltd.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to equity transactions:
- Pre-Funded Warrants Issued: 513,140 shares at an exercise price of $0.0001 per share.
- Shares Previously Exercised: 459,140 shares.
- Shares Exercised on June 18, 2025: 54,000 shares.
- Total Shares Issued from Warrants: 513,140 shares.
Material Changes
The material change reported is the full exercise of the Pre-Funded Warrants granted to Armistice Capital Master Fund Ltd. As of June 18, 2025, no Pre-Funded Warrants remain outstanding. This transaction increases the company's outstanding common stock count by 54,000 shares relative to the prior reporting period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies beyond the completion of the warrant exercise. No unusual items were reported.
Investor Verification Checklist
- Verify the updated total share count and fully diluted share count following the issuance of 54,000 new shares.
- Confirm the cash proceeds received from the exercise of the 54,000 warrants at $0.0001 per share.
- Review the May 15, 2025 Form 8-K for the full terms of the original Securities Purchase Agreement with Armistice Capital Master Fund Ltd.